

# Contents

## CHAPTER 1

### Neurophysiology of Basal Ganglia

W. SCHULTZ . . . . .	1
A. Introduction . . . . .	1
B. Electrophysiology of Connections . . . . .	2
I. Peripheral and Cerebral Input to Basal Ganglia . . . . .	2
1. Striatum . . . . .	2
a. Peripheral Input . . . . .	2
b. Cerebral Input . . . . .	3
2. Nucleus Subthalamicus . . . . .	4
3. Substantia Nigra . . . . .	4
II. Internal Basal Ganglia Connections . . . . .	4
1. Nigrostriatal Dopamine System . . . . .	5
a. Substantia Nigra . . . . .	5
b. Striatum . . . . .	5
2. Striatopallidal . . . . .	6
3. Striatonigral . . . . .	7
4. Nucleus Subthalamicus . . . . .	7
5. Nucleus Tegmenti Pedunculopontinus . . . . .	8
III. Output of Basal Ganglia . . . . .	8
1. Pallidothalamic . . . . .	8
2. Nigrothalamic . . . . .	9
3. Pallidohabenular . . . . .	9
4. Nigrocollicular . . . . .	9
5. Nucleus Tegmenti Pedunculopontinus . . . . .	10
C. Motor Control Functions . . . . .	10
I. Anatomic Considerations . . . . .	10
II. Lesions, Cooling, and Local Drug Injections . . . . .	11
1. Striatum . . . . .	11
2. Globus Pallidus . . . . .	11
3. Substantia Nigra Pars Reticulata . . . . .	12
4. Nucleus Subthalamicus . . . . .	12
III. Neuronal Recordings . . . . .	13
1. Striatum . . . . .	13
2. Globus Pallidus . . . . .	14
3. Substantia Nigra Pars Reticulata . . . . .	15

4. Nucleus Subthalamicus . . . . .	15
D. Higher Functions . . . . .	16
I. Anatomy of Connections . . . . .	16
1. Cortical Input . . . . .	16
2. Limbic Input . . . . .	16
3. Output . . . . .	17
II. Neuropsychologic Deficits After Lesions . . . . .	17
III. Neuronal Recordings . . . . .	18
1. Untrained Behavior . . . . .	18
2. Context-Dependent Responses to Directly Triggering Stimuli . . . . .	18
3. Preparation to Act . . . . .	20
a. Nondiscriminative Instructions . . . . .	21
b. Discriminative Instructions . . . . .	21
c. Delayed Response Tasks . . . . .	22
d. Self-Initiated Acts . . . . .	23
E. Dopaminergic Functions . . . . .	24
I. Animal Models of Parkinsonism . . . . .	24
1. Monkey . . . . .	24
2. Rodent . . . . .	25
II. Impulse activity of Dopamine Neurons . . . . .	26
1. Peripheral Input Under Anesthesia . . . . .	26
2. Relations to Behavior . . . . .	27
a. Execution of Movements . . . . .	27
b. Responses to Stimuli . . . . .	27
c. Preparation to Act . . . . .	28
3. Comparison with Deficits . . . . .	29
F. Conclusions . . . . .	30
I. Functional Connectivity . . . . .	30
1. Lateralization of Function . . . . .	30
2. Disinhibition of Target Structures . . . . .	30
3. The "Extrapyramidal Motor System" . . . . .	31
II. Dopamine System . . . . .	31
1. Mismatch Between Negative and Positive Image . . . . .	31
2. Paradoxical Kinesia . . . . .	31
3. Neuronal Activity in Target Areas of DA Neurons . . . . .	32
III. Corticostriatal Activity . . . . .	32
References . . . . .	33

## CHAPTER 2

### Pathology of Parkinson's Syndrome

K. JELLINGER. With 9 Figures . . . . .	47
A. Introduction . . . . .	47
B. Cytoskeletal Pathology . . . . .	49
I. Lewy Bodies . . . . .	49
II. Hirano Bodies . . . . .	51

III.	Intracytoplasmic Eosinophilic Granules . . . . .	51
IV.	Marinesco Bodies . . . . .	51
V.	Neurofibrillary Tangles . . . . .	51
	1. Alzheimer's Neurofibrillary Tangles . . . . .	51
	2. Tangles in Progressive Supranuclear Palsy . . . . .	52
VI.	Granulovacuolar Degeneration . . . . .	52
VII.	Axonal Dystrophy and Grumelous Degeneration . . . . .	53
VIII.	Neuritic Plaques and Amyloid . . . . .	53
C.	Major Types of Parkinsonism . . . . .	53
I.	Parkinson's Disease . . . . .	54
II.	Parkinson's Disease and Alzheimer's Disease . . . . .	59
III.	Diffuse Lewy Body Disease . . . . .	62
IV.	Multisystem Degenerations . . . . .	63
V.	Parkinson-Dementia Complex . . . . .	63
VI.	Progressive Supranuclear Palsy . . . . .	64
VII.	Postencephalitic Parkinsonism . . . . .	64
VIII.	Vascular or Multi-infarct Parkinsonism . . . . .	66
IX.	Toxic Parkinsonism . . . . .	66
X.	Symptomatic Parkinsonism . . . . .	67
D.	Morphological Correlates of Pathobiochemistry . . . . .	67
I.	Dopaminergic System . . . . .	67
	1. Substantia Nigra and Ventral Tegmental Area . . . . .	68
	2. Striatopallidum and Other CNS Areas . . . . .	71
II.	Noradrenergic System . . . . .	72
	1. Locus Ceruleus . . . . .	72
	2. Dorsal Vagal Nucleus . . . . .	75
III.	Serotonergic System . . . . .	75
IV.	Cholinergic Systems . . . . .	77
	1. Nucleus Basalis of Meynert . . . . .	77
	2. Nucleus Tegmenti Pedunculopantinus . . . . .	80
	3. Westphal-Edinger Nucleus . . . . .	81
V.	Peptidergic Systems . . . . .	81
E.	Morphological Effects of Levodopa Treatment . . . . .	82
F.	Pathology of Dementia in Parkinson's Disease . . . . .	82
G.	Concluding Remarks . . . . .	91
	References . . . . .	94

## CHAPTER 3

### Biochemical Neuroanatomy of the Basal Ganglia

E.G. McGEER and P.L. McGEER. With 12 Figures. . . . . 113

A.	Introduction . . . . .	113
B.	Neurotransmitters in the Extrapyramidal System . . . . .	114
I.	Type I: Amino Acid Neurotransmitters . . . . .	114
II.	Type II: Amine Neurotransmitters . . . . .	116
III.	Type III: Peptide Neurotransmitters . . . . .	118

IV. Receptor Subtypes . . . . .	120
C. Heterogeneities in Extrapyramidal Nuclei . . . . .	121
I. Mosaics or Gradients . . . . .	121
II. Differences Between Caudate, Putamen, and Nucleus Accumbens . . . . .	123
D. Interconnections in the Extrapyramidal System . . . . .	124
E. Some Hypotheses as to the Role of Various Tracts in the Extrapyramidal System . . . . .	128
F. Conclusions . . . . .	130
G. Appendix: Afferents and Efferents of Extrapyramidal Nuclei . . . . .	130
References . . . . .	137

## CHAPTER 4

### Receptors in the Basal Ganglia

A. B. YOUNG and J. B. PENNEY. With 2 Figures . . . . .	149
A. Introduction . . . . .	149
B. Neurotransmitter Receptor Properties . . . . .	149
C. Dopamine Receptors . . . . .	150
I. Properties and Subtypes . . . . .	150
II. Distribution . . . . .	152
III. Dopamine Receptors in Parkinson's Disease . . . . .	155
IV. In Vivo Studies . . . . .	156
D. GABA Receptors . . . . .	156
E. Acetylcholine Receptors . . . . .	156
F. Opiate Receptors . . . . .	157
G. Other Receptors . . . . .	158
H. Summary . . . . .	158
References . . . . .	159

## CHAPTER 5

### Imaging the Basal Ganglia

W. R. W. MARTIN. With 3 Figures . . . . .	165
A. Introduction . . . . .	165
B. Structural Imaging Techniques . . . . .	166
I. Methodology . . . . .	166
1. X-Ray Computed Tomography (CT) . . . . .	166
2. Magnetic Resonance Imaging (MRI) . . . . .	166
II. Parkinson's Disease . . . . .	166
III. Huntington's Disease . . . . .	167
IV. Dystonia . . . . .	167
V. Other Movement Disorders . . . . .	168
C. Functional Imaging Techniques . . . . .	168
I. Methodology . . . . .	168
1. Positron Emission Tomography (PET) . . . . .	168

a. Cerebral Blood Flow and Metabolism . . . . .	168
b. Presynaptic Dopaminergic Function . . . . .	169
c. Dopamine Receptors . . . . .	171
2. Single-Photon Emission Computed Tomography (SPECT) . . . . .	172
II. Parkinson's Disease . . . . .	172
III. Huntington's Disease . . . . .	174
IV. Dystonia . . . . .	177
D. Conclusions . . . . .	178
References . . . . .	178

## CHAPTER 6

### The Neurochemical Basis of the Pharmacology of Parkinson's Disease

O. HORNYKIEWICZ. With 4 Figures . . . . .	185
A. Introduction . . . . .	185
B. The Basic Neurochemical Pathology of Parkinson's Disease . . . . .	185
I. The Nigrostriatal Dopamine Neuron System . . . . .	186
II. Extrastriatal Dopamine Neurons . . . . .	187
III. Nondopamine Neuron Systems . . . . .	188
C. Pathophysiologic and Pharmacologic Significance of the Biochemical Brain Abnormalities in Parkinson's Disease . . . . .	189
I. Nigrostriatal Dopamine Loss . . . . .	189
II. Extrastriatal Dopamine Changes . . . . .	190
III. Nondopamine Changes . . . . .	190
1. Changes in the Basal Ganglia . . . . .	190
a. Norepinephrine . . . . .	191
b. Acetylcholine . . . . .	192
c. $\gamma$ -Aminobutyric Acid . . . . .	192
d. Serotonin, Neuropeptides . . . . .	193
2. Changes Outside the Basal Ganglia . . . . .	193
D. Striatal Dopamine Deficiency and the Pharmacotherapy of Parkinson's Disease: Special Aspects of Dopamine Substitution . . . . .	194
I. Compensatory Changes in the Nigrostriatal Dopamine Neurons . . . . .	194
II. Compensated and Decompensated Stages of Parkinson's Disease and the Goal of Dopamine Substitution . . . . .	195
III. The Role of the Compensatory Changes for Dopamine Substitution . . . . .	196
1. The Role of Presynaptic Overactivity . . . . .	196
2. The Importance of Postsynaptic Supersensitivity for the Pharmacology of Parkinson's Disease . . . . .	196
a. Special Sensitivity of the Parkinsonian Striatum to Dopamine Substitution . . . . .	197
b. Regional Selectivity of Dopamine Substitution Therapy . . . . .	197
c. New approaches to Dopamine Substitution . . . . .	198
$\alpha$ . Selective Dopamine Autoreceptor Agonists as a New Class of Specific Potential Antiparkinsonian Agents . . . . .	198

β. Autografting of Dopamine-Producing Cells into the Parkinsonian Striatum . . . . .	198
E. Prospects of Preventive Drug Treatment in Parkinson's Disease . . . . .	199
References . . . . .	199

## CHAPTER 7

### Pyridine Toxins

J.W. LANGSTON and I. IRWIN. With 3 Figures . . . . .	205
A. Introduction . . . . .	205
B. What are Pyridines? . . . . .	205
I. Historical Background . . . . .	205
II. Structure and Chemistry . . . . .	205
III. Biologic Role . . . . .	207
IV. Distribution of Pyridines . . . . .	207
C. Pyridines as Toxins . . . . .	208
I. History . . . . .	208
II. Animal Models . . . . .	209
1. Invertebrates . . . . .	209
2. Amphibia . . . . .	210
3. Rodents . . . . .	210
4. Cat . . . . .	211
5. Dog . . . . .	211
6. Primates . . . . .	212
D. Factors Affecting Toxicity . . . . .	212
I. Mechanism of Action . . . . .	213
II. Toxicokinetic and Toxicodynamic Effects . . . . .	213
III. Species Differences . . . . .	214
IV. Neuromelanin . . . . .	215
V. Age Differences . . . . .	216
E. Pyridines as Protectors? . . . . .	217
F. Toxic Tetrahydropyridines: A Growing Family . . . . .	218
G. Pyridines and Parkinson's Disease . . . . .	220
References . . . . .	220

## CHAPTER 8

### The Relationship Between Parkinson's Disease and Other Movement Disorders

J. JANKOVIC. With 4 Figures. . . . .	227
A. Introduction . . . . .	227
B. Secondary Parkinsonism . . . . .	232
I. Drug-Induced Parkinsonism . . . . .	232
II. Toxin-Induced Parkinsonism . . . . .	233
1. Manganese . . . . .	233
2. Carbon Monoxide . . . . .	234

3. Cyanide . . . . .	236
4. Carbon Disulfide . . . . .	236
5. Other Toxins . . . . .	237
III. Metabolic Causes of Parkinsonism . . . . .	238
1. Hypoparathyroidism . . . . .	238
2. Acquired Hepatocerebral Degeneration . . . . .	239
3. Other Metabolic Causes . . . . .	239
IV. Postencephalitic Parkinsonism and Slow Virus Infections . . . . .	239
V. Vascular Parkinsonism . . . . .	242
VI. Brain Tumors . . . . .	243
VII. Trauma . . . . .	244
VIII. Hydrocephalus . . . . .	245
IX. Syringomesencephalia . . . . .	246
C. Sporadic Multiple System Degenerations (Parkinsonism-Plus) . . . . .	246
I. Progressive Supranuclear Palsy . . . . .	246
II. Shy-Drager Syndrome . . . . .	249
III. Olivopontocerebellar Atrophies . . . . .	250
IV. Corticobasal Degeneration . . . . .	252
V. Parkinsonism-Dementia-ALS Complex . . . . .	252
VI. Striatonigral Degeneration . . . . .	254
D. Inherited Multiple System Degenerations . . . . .	256
I. Huntington's Disease . . . . .	256
II. Wilson's Disease . . . . .	258
III. Hallervorden-Spatz Disease . . . . .	258
IV. Other Familial Parkinsonian Syndromes . . . . .	259
V. Familial Basal Ganglia Calcifications . . . . .	259
VI. Neuroacanthocytosis . . . . .	259
References . . . . .	260

## CHAPTER 9

### Evaluation of Parkinson's Disease

H. TERÄVÄINEN, J. TSUI and D.B. CALNE. With 2 Figures . . . . .	271
A. Introduction . . . . .	271
B. Subjective Assessment . . . . .	271
C. Objective Assessment . . . . .	275
I. Tremor . . . . .	275
II. Rigidity . . . . .	276
III. Hypokinesia . . . . .	277
D. Summary . . . . .	278
References . . . . .	278

## CHAPTER 10

### Clinical Trials for Parkinson's Disease

J.K. TSUI, H. TERÄVÄINEN and D.B. CALNE . . . . .	281
---	-----

A. Introduction . . . . .	281
B. Phases . . . . .	281
C. Design . . . . .	282
D. Recruitment . . . . .	284
E. Assessment . . . . .	284
F. Statistical Analysis . . . . .	285
G. Conclusions . . . . .	286
References . . . . .	286

## CHAPTER 11

### Experimental Therapeutics Directed at the Pathogenesis of Parkinson's Disease

I. SHOULSON. With 1 Figure . . . . .	289
A. Introduction . . . . .	289
B. General Strategies for Prevention and Protection . . . . .	289
C. Antioxidative Pharmacotherapies . . . . .	290
D. Clinical Trial of Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) . . . . .	293
I. Pilot Studies and Candidate Drugs . . . . .	293
II. Factorial Design . . . . .	295
III. Major Response Variable . . . . .	295
IV. Sample Size Estimates . . . . .	297
V. Symptomatic or Protective Effects? . . . . .	298
VI. Recruitment . . . . .	299
VII. Potential Pitfalls . . . . .	299
E. Animal Models . . . . .	300
F. Neural Grafting . . . . .	301
G. Summary . . . . .	301
References . . . . .	302

## CHAPTER 12

### Anticholinergic Drugs and Amantadine in the Treatment of Parkinson's Disease

A. E. LANG and R. D. G. BLAIR . . . . .	307
A. Introduction . . . . .	307
B. Anticholinergics . . . . .	307
I. Introduction . . . . .	307
II. Mechanism of Action . . . . .	308
III. Pharmacokinetics . . . . .	309
IV. Clinical Effects . . . . .	309
V. Side Effects . . . . .	311
VI. Conclusions . . . . .	312
C. Amantadine . . . . .	312
I. Introduction . . . . .	312



II. Mechanism of Action . . . . .	313
III. Pharmacokinetics . . . . .	314
IV. Clinical Effects . . . . .	314
V. Side Effects . . . . .	315
VI. Conclusions . . . . .	317
References . . . . .	318

## CHAPTER 13

### The Pharmacology of Levodopa in Treatment of Parkinson's Disease: An Update

P.A. LEWITT . . . . .	325
A. Introduction . . . . .	325
B. The Efficacy of Levodopa in Parkinsonism . . . . .	326
I. Background . . . . .	326
II. Clinical Effectiveness of Levodopa in Parkinson's Disease . . . . .	328
III. Use of Levodopa in Other Forms of Parkinsonism and Other Movement Disorders . . . . .	330
IV. Therapeutic Principles for Levodopa . . . . .	331
C. Clinical Aspects of Levodopa Pharmacokinetics, Pharmacodynamics, and Metabolism . . . . .	333
I. Levodopa Pharmacokinetics . . . . .	333
II. Levodopa Metabolism: 3- <i>O</i> -Methyldopa and Other Metabolites . . . . .	337
III. Other Metabolic Effects of Levodopa . . . . .	338
D. Other Effects of Levodopa . . . . .	340
E. Pharmacodynamics of Levodopa Therapy . . . . .	342
F. Mechanism of Action of Levodopa in Parkinsonism . . . . .	344
G. Levodopa Preparations . . . . .	348
I. Decarboxylase Inhibitors . . . . .	348
II. Sustained-Release Forms . . . . .	352
III. Enhanced Delivery and Uptake . . . . .	354
H. Therapeutic Uses for Levodopa Other Than Parkinsonism . . . . .	354
J. Clinical Issues Regarding Initiation of Levodopa Therapy . . . . .	355
I. "Early" Versus "Delayed" Use of Levodopa . . . . .	355
II. "Low Dose" Levodopa Regimens . . . . .	359
K. Clinical Issues Regarding "Drug Holiday" . . . . .	359
References . . . . .	361

## CHAPTER 14

### Adverse Effects of Levodopa in Parkinson's Disease

S.FAHN . . . . .	385
A. Historical Aspects of Adverse Effects . . . . .	385
B. Classification, Pathophysiology, and Treatment of Adverse Effects . . . . .	389
I. Peripheral Adverse Effects . . . . .	392
1. Gastrointestinal Symptoms . . . . .	392

2. Cardiac Dysrhythmias . . . . .	393
3. Melanoma . . . . .	393
II. Central Adverse Effects . . . . .	393
1. Dyskinesias . . . . .	393
a. Chorea . . . . .	393
$\alpha$ . Peak-Dose Chorea . . . . .	393
$\beta$ . Diphasic Chorea . . . . .	393
b. Dystonia . . . . .	394
$\alpha$ . Peak-Dose Dystonia . . . . .	394
$\beta$ . Diphasic Dystonia . . . . .	394
$\gamma$ . "Off" Dystonia . . . . .	394
c. Myoclonus . . . . .	395
d. Simultaneous Dyskinesias with Parkinsonism . . . . .	395
2. Tachykinesia with Hypokinesia . . . . .	395
a. Tachyphemia . . . . .	395
b. Running Gait . . . . .	396
3. Fluctuations . . . . .	396
a. "Wearing-Off" . . . . .	396
b. "Sudden Off" . . . . .	397
c. "Random Off" . . . . .	397
d. Yo-yo-ing . . . . .	398
e. Episodic Failure to Respond to Each Dose . . . . .	398
f. "Delayed On" . . . . .	398
g. Weak Levodopa Response at End of Day . . . . .	399
h. Response Varies in Relation to Meals . . . . .	399
4. "Freezing" . . . . .	399
5. Mental Changes . . . . .	400
6. Loss of Efficacy . . . . .	400
a. Caused by Pyridoxine . . . . .	400
b. With Continuing Treatment . . . . .	400
7. Miscellaneous . . . . .	401
a. Altered Sleep-Wake Cycle . . . . .	401
b. Hypersexuality . . . . .	401
c. Akathisia . . . . .	402
d. Sweating . . . . .	403
e. Postural Hypotension . . . . .	403
f. Respiratory Distress . . . . .	403
g. Falling . . . . .	404
h. Pain . . . . .	404
j. Increased Parkinsonism . . . . .	404
k. "Neuroleptic Malignant Syndrome" . . . . .	404
References . . . . .	405

## CHAPTER 15

**Monoamine Oxidase Inhibitors in Parkinson's Disease**

M. SANDLER and V. GLOVER. With 8 Figures . . . . . 411

A. Introduction . . . . .	411
B. The Inhibition of Dopamine Oxidation by (-)-Deprenyl . . . . .	414
C. Cellular Localisation of MAO in the Brain . . . . .	416
D. Safety of (-)-Deprenyl . . . . .	416
E. Assessment of MAO Inhibition In Vivo . . . . .	418
F. Distribution of (-)-Deprenyl in Brain and Body . . . . .	419
G. Metabolism of (-)-Deprenyl to Amphetamine . . . . .	420
H. Other Actions of (-)-Deprenyl . . . . .	421
J. MAO and MPTP . . . . .	422
K. Postscript . . . . .	423
References . . . . .	426

## CHAPTER 16

**Clinical Actions of L-Deprenyl in Parkinson's Disease**

M. D. YAHR and H. KAUFMANN . . . . .	433
A. Introduction . . . . .	433
B. Pharmacology . . . . .	434
C. Clinical Trials . . . . .	435
I. Combined Use of Deprenyl with Levodopa . . . . .	435
II. L-Deprenyl as Monotherapy . . . . .	438
D. Summary . . . . .	438
References . . . . .	439

## CHAPTER 17

**Update on Bromocriptine in Parkinson's Disease**

A. N. LIEBERMAN and M. GOLDSTEIN. With 9 Figures . . . . .	443
A. Introduction . . . . .	443
B. Side Effects of Levodopa . . . . .	444
C. Mechanisms for Decline in Response . . . . .	445
D. Treatment of Response Fluctuations: Bromocriptine . . . . .	446
E. Studies of Bromocriptine Therapy . . . . .	449
F. Pharmacology of Bromocriptine . . . . .	454
References . . . . .	456

## CHAPTER 18

**Pergolide in the Treatment of Parkinson's Disease**

C. H. MARKHAM and S. G. DIAMOND. With 3 Figures . . . . .	459
A. Chemistry and Pharmacology . . . . .	459
B. Clinical Studies . . . . .	460
I. Open-Label Studies . . . . .	460
II. Double-Blind Studies . . . . .	462
III. A Long-term Follow-up Study . . . . .	462

C. How to Administer . . . . .	465
D. Side Effects . . . . .	467
References . . . . .	468

## CHAPTER 19

**Lisuride Pharmacology and Treatment of Parkinson's Disease**

G.GOPINATHAN, R.HOROWSKI and I.SUCHY . . . . .	471
A. Chemistry . . . . .	471
B. Toxicology . . . . .	471
C. Pharmacokinetics . . . . .	472
D. Biochemistry and Pharmacology . . . . .	473
I. Receptor Binding . . . . .	473
II. Biochemistry . . . . .	475
III. Pharmacology . . . . .	475
IV. Neurophysiology . . . . .	478
E. Clinical Applications . . . . .	481
I. Clinical Pharmacology . . . . .	481
II. Applications in Clinical Endocrinology . . . . .	482
F. Lisuride in Neurological Diseases . . . . .	487
I. Parkinson's Disease and Related Disorders . . . . .	487
1. Oral Application . . . . .	488
2. Parenteral Application . . . . .	497
3. Subcutaneous Lisuride: Continuous Dopaminergic Stimulation . . . . .	498
II. Other Motor Disturbances . . . . .	499
III. Migraine . . . . .	500
G. Conclusion . . . . .	501
References . . . . .	501

## CHAPTER 20

**Domperidone and Parkinson's Disease**

J.D. PARKES. With 1 Figure . . . . .	515
A. Introduction . . . . .	515
B. Domperidone . . . . .	516
I. Animal Pharmacology . . . . .	516
II. Pharmacokinetics in Humans . . . . .	516
III. Behavioural Effects . . . . .	517
IV. Effect on the Pharmacokinetic Behaviour of Levodopa . . . . .	518
C. Effect of Domperidone on Levodopa Response . . . . .	519
I. Therapeutic Response to Levodopa in Parkinsonism . . . . .	519
II. Dopamine Agonist-Induced Sickness . . . . .	522
III. Levodopa-Associated Cardiovascular Problems . . . . .	522
1. Domperidone- and Levodopa-Induced Hypotension . . . . .	522
2. Domperidone and Cardiac Dysrhythmias . . . . .	523

3. Domperidone and Cerebral Blood Flow . . . . .	523
IV. Levodopa-Associated Respiratory Problems . . . . .	523
D. Comparison of Domperidone with Metoclopramide and Other Neuroleptics in the Management of Parkinson's Disease . . .	525
E. Comparison of Domperidone with Decarboxylase Inhibitors in the Management of Parkinson's Disease . . . . .	526
References . . . . .	527

## CHAPTER 21

### **New Routes of Administration for Antiparkinsonian Therapy**

J.A. OBESO and S.M. STAHL. With 2 Figures . . . . .	531
A. Introduction . . . . .	531
B. Delivery Methods . . . . .	532
I. Enteral Administration . . . . .	532
II. Intravenous Administration . . . . .	533
III. Subcutaneous Administration . . . . .	533
IV. Transcutaneous Administration . . . . .	534
C. Clinical Studies . . . . .	534
I. Enteral Routes . . . . .	534
II. Intravenous Administration . . . . .	535
1. Levodopa . . . . .	535
2. Lisuride . . . . .	536
3. Apomorphine . . . . .	537
III. Subcutaneous Infusions . . . . .	537
IV. Transdermal Application . . . . .	539
D. Conclusion . . . . .	539
References . . . . .	539

## CHAPTER 22

### **Treatment of Parkinsonian Features in Neurological Disorders Other than Parkinson's Disease**

R.F. PEPPARD and D.B. CALNE . . . . .	543
A. Introduction . . . . .	543
B. Drug-Induced Parkinsonism . . . . .	543
C. Wilson's Disease . . . . .	547
D. Multiple System Degenerations . . . . .	549
I. Striatonigral Degeneration . . . . .	549
II. Olivopontocerebellar Atrophy . . . . .	549
III. Shy-Drager Syndrome . . . . .	550
IV. Progressive Supranuclear Palsy . . . . .	550
V. Senile Parkinsonism . . . . .	551
VI. The ALS-Parkinson-Dementia Complex of Guam . . . . .	551
VII. Joseph Disease . . . . .	551

E. Other Types of Parkinsonism . . . . .	551
I. Postencephalitic Parkinsonism . . . . .	551
II. Parkinsonism Due to Toxins . . . . .	552
III. Hypoparathyroidism . . . . .	552
IV. Huntington's Disease . . . . .	552
F. Conclusions . . . . .	552
References . . . . .	552

## CHAPTER 23

**Management of Psychiatric Symptoms in Parkinson's Disease**

H.L. KLAWANS and C.M. TANNER . . . . .	557
A. Introduction . . . . .	557
B. Depression . . . . .	557
C. Psychosis and Related Disorders . . . . .	560
I. Early Onset Psychosis . . . . .	560
II. Late Onset Psychosis . . . . .	561
D. Drug-Induced Hallucinatory Syndromes . . . . .	564
I. Anticholinergic Delirium . . . . .	564
II. Hallucinations with a Clear Sensorium . . . . .	565
E. Treatment of Psychosis . . . . .	566
F. Aberrant Sexual Behavior . . . . .	568
References . . . . .	568

## CHAPTER 24

**Intracranial grafts for the treatment of Parkinson's Disease**

A. FINE and H.A. ROBERTSON . . . . .	573
A. Introduction . . . . .	573
B. Sources of Dopamine-Secreting Cells . . . . .	574
C. Neural and Adrenal Grafts in Animal Models of Parkinson's Disease . . . . .	575
I. Studies in the Rat . . . . .	576
II. Studies in Primates . . . . .	578
D. Dopaminergic Grafts in Humans . . . . .	580
E. Conclusions . . . . .	583
References . . . . .	583